Compound V is a small molecule with potential therapeutic benefits in patients with obesity. An early clinical safety trial produced two patients with liver enzyme elevations. Using a combination of in vitro assays and in silico modeling, this study investigated whether Compound V is capable of inducing hepatocyte cell death, and if so, what mechanism(s) may be involved and to what extent the compound concentration in the liver plays a role.
By Vinal V. Lakhani, Grant Generaux, Scott Q. Siler, Brett A. Howell, Jeffrey L. Woodhead
Presented at SLP MIDD+ Virtual Conference March 3-4, 2021